research@armsecurities.com.ng +234 1 270 1652



Nigerian Breweries Plc. (NB.NL)

Initial View


A disappointing end to the year

Similar to what we saw in Q320, Nigerian Breweries (NB) recorded a strong YoY growth of 18% in their revenue which printed at №103 billion over Q420. However, cost of sales grew by an astonishing 42% which dragged gross profit down by 18%YoY to №28.74 billion. Despite a 14%YoY fall in OPEX, the sharp increase in cost of sales meant that EBIT fell 30%YoY to №7.11 billion. Higher finance costs led net finance expense higher by 67%YoY which in turn helped bring PBT lower by 90%YoY to №599 million.

- Rising costs overshadow revenue growth: Revenue grew for a second consecutive do you mean second consecutive quarter in Q420 by 18%YoY to print at an impressive №103 billon. The price increase from earlier this year most certainly played a part in the higher revenue but until we speak to management during their conference call it is tough to determine what role, if any, quantity played during the quarter. However, the main story from the top line is the 42%YoY growth in cost of sales to №74.26 billion. This gives a cost-to-sales margin of 72% which is comfortably the highest NB have reported in the past 8 years. Leading this rise in costs was a 39%YoY increase in the cost of raw materials to №50 billion, a result of the rising inflation and currency depreciation. There was also a charge of №5.42 billion for variable lease expenses which was not there last year while the cost for repairs and maintenance doubled to №4.95 billion. Gross profit fell 18%YoY to №28.74 billion which translates to a margin of 28% (Q419: 40%).
- While cost of sales is seemingly spiraling out of control, NB appear to have a firm grip on OPEX which declined on a YoY basis for the 3rd consecutive quarter. In Q420, OPEX declined by 13.5%YoY to N21.87 billion, a margin of 21% (Q419: 29%). This fall came as both S&D (-8.2%YoY) and administrative costs (-34.4%YoY) declined over the period. EBIT printed at N7.1 billion, a 29%YoY fall when compared to Q419's N10.03 billion, which represents an EBIT margin of 7% (Q419: 12%).
- NB's net finance cost rose 67%YoY to \$\frac{N}{6}.52\$ billion following the undesirable combination of declining finance income (-7.2%YoY) and rising finance expense (+66.4%YoY). The former was as a result of lower interest from bank deposits while the latter arose from a higher net loss on FX transactions and interest on lease liabilities.

Rating NEUTRAL Price №58.70 FVE №53.20 52-week range №22.00 - №63.25 Market Cap (№bn) 469.418 1-month Avg. Vol 274,301 Current. PE 63.61

NB:NL - Share Price Trend



Analyst

Temitayo Peters
temitayo.peters@arm.com.ng

These led PBT lower by 90%YoY to \$\frac{\text{\text{\text{N}}}}{599}\$ million while PAT was lower by 93%YoY at \$\frac{\text{\text{\text{\text{\text{N}}}}}{29}}{200}\$ million.

- Combing through the balance sheet we see that NB halved their receivables QoQ to ¥11.42 billion while payables rose by 25% to ¥139.2 billion. Cash and cash equivalents fell by 44% between the end Q320 and Q420 to ¥30.37 billion on the back of higher VAT paid and acquisition of PPE. Elsewhere, deposit for imports, which represent Naira deposits for foreign currencies purchased for funding of letters of credit and forwards, almost quadrupled to ¥11.58 billion (Q320: ¥3.76 billion).
- Looking at the whole of FY20, revenue grew by 4.3% to №337.04 billion (FY19: №323 billion) which is the highest revenue they have posted since 2017. According to parent company Heineken, this was supported by volume growth with premium beer, led by Tiger and Heineken, experiencing a double-digit growth. Additionally, prices are higher when compared to last year. But an 18.9% spike in cost of sales meant gross profit came in 10% lower at №118.69 billion (FY19: №131.25 billion) which translates to a gross profit margin of 35% (FY19: 40%). OPEX was 7.4% lower on a YoY basis but EBIT still declined by 16%YoY to №29.61 billion. The corresponding margin of 9% is the lowest margin we have in our records for NB. Net finance cost rose 52% over the period leading PBT 50% lower at №11.58 billion while PAT printed at №7.37 billion.
- Our current FVE for Nigerian Breweries is \$\frac{\textbf{N}}{4}53.20\$ but after getting clarity from management on these results during their conference call this Friday we will likely be adjusting our estimates. In the meantime, we place a **NEUTRAL** recommendation on the stock.

Summary of Results and Forecasts

| ncome Statement (N'000) * | Q419 | Q120 | Q220 | Q320 | Q420 |
|---------------------------|-------------|-------------|-------------|-------------|-------------|
| Revenue | 87,328,037 | 83,204,327 | 68,651,759 | 82,228,896 | 103,007,480 |
| cogs | 52,250,072 | 48,334,963 | 44,379,706 | 51,422,855 | 74,264,074 |
| Gross Profit | 35,077,965 | 34,869,364 | 24,272,053 | 30,806,041 | 28,743,406 |
| Operating Cost | 25,275,138 | 24,136,166 | 20,293,057 | 23,614,090 | 21,870,604 |
| Operating Profit | 10,032,753 | 10,914,560 | 4,131,764 | 7,443,787 | 7,114,891 |
| Interest Income | 32,080 | 7,944 | 115,841 | 92,721 | 29,777 |
| Interest Expense | 3,934,937 | 2,646,641 | 4,177,838 | 4,904,663 | 6,545,597 |
| РВТ | 6,129,896 | 8,275,863 | 69,767 | 2,631,845 | 599,071 |
| Tax | 2,299,179 | 2,770,311 | 14,146 | 1,281,736 | 170,275 |
| PAT | 3,830,717 | 5,505,552 | 55,621 | 1,350,109 | 428,796 |
| Balance Sheet (₦ '000) * | Q419 | Q120 | Q220 | Q320 | Q420 |
| Fixed Assets | 310,248,537 | 323,422,780 | 326,517,130 | 338,957,954 | 352,526,790 |
| Inventories | 38,520,328 | 40,885,215 | 40,045,515 | 42,906,709 | 36,087,210 |
| Receivables | 21,307,218 | 28,608,692 | 32,858,347 | 24,060,761 | 11,417,423 |
| Liabilities | | | | | |
| Payables | 102,782,561 | 100,334,419 | 97,250,295 | 111,030,790 | 139,200,670 |
| Non-current Liabilities | 75,498,612 | 57,018,511 | 60,654,864 | 73,983,521 | 74,210,570 |
| Total liabilities | 215,027,543 | 258,103,803 | 303,227,445 | 304,940,510 | 284,642,306 |
| Shareholders' fund | 167,749,979 | 173,303,175 | 160,891,616 | 162,289,367 | 161,179,042 |
| Key Ratios | Q419 | Q120 | Q220 | Q320 | Q420 |
| Gross Margin | 40.2% | 41.9% | 35.4% | 37.5% | 27.9% |
| EBIT Margin | 11.5% | 13.1% | 6.0% | 9.1% | 6.9% |
| PBT Margin | 7.0% | 9.9% | 0.1% | 3.2% | 0.6% |
| PAT Margin | 4.4% | 6.6% | 0.1% | 1.6% | 0.4% |
| EPS | 0.48 | 0.69 | 0.01 | 0.17 | 0.05 |

ARM ratings and recommendations

ARM now employs a two-tier rating system which is based on systemic importance of the security under review and the deviation of our target price for the stock from current market price. We characterize systemic importance as a function of a stock's ranking among the group of top 20 stocks by NSE market capitalization over a trailing 6-month period (minimum) to the review date. We adopt a 5-point rating system for this category of stocks and a 3-point rating system for stocks outside this group. The choice of top 20 stocks arises from the consideration that this group of stocks constitutes >75% of overall market capitalization and stocks outside this group are generally less liquid and individually account for <<1% of market capitalization. For stocks in both categories, the basis for ratings subject to target price deviation is outlined below:

| TOP 20 | | NON-TOP 20 | |
|-------------|------------|------------|-----------|
| Rating | Deviation | Rating | Deviation |
| STRONG BUY | >20% | BUY | >20% |
| OVERWEIGHT | 10% — 20 % | NEUTRAL | 5% — 20 % |
| NEUTRAL | 0% — 10% | SELL | <5% |
| UNDERWEIGHT | -5% — 0% | | |
| SELL | <-5% | | |

| RECOMMENDATION KEY | | | | |
|--------------------|---|--|--|--|
| Rating | Recommendation | | | |
| BUY | Accumulate security to a substantial extent constrained only by portfolio diversification considerations | | | |
| OVERWEIGHT | Accumulate security to an extent moderated by cognizance of its benchmark weight | | | |
| | Maintain status quo for security with respect to current holding—i.e. keep if already holding and don't buy otherwise—subject to reasonable | | | |
| NEUTRAL | portfolio constraints | | | |
| UNDERWEIGHT | Minimize exposure to security taking cognizance of its index weighting | | | |
| SELL | Sell-off security completely from portfolio | | | |

ARM | Classification: PUBLIC

Copyright © 2021 ARM Securities Limited ("ARMS").

All rights reserved. Unauthorised use, reproduction, distribution, or disclosure of this document is strictly prohibited.

This material has been issued by ARM Securities Limited, a member of the Asset and Resource Management ("ARM") Group, and a Company regulated by the Nigerian Securities & Exchange Commission. The analyst(s) primarily responsible for preparing this research report, in whole or in part, certifies that with respect to each security or issuer covered; all of the views expressed accurately reflect his/her personal views about the subject securities and issuers and no part of his/her compensation was, is, or will be, directly or indirectly, related to the inclusion of specific recommendations or views in the report.

This research report is based on information from sources that ARMS and its analysts believe to be reliable. Neither ARMS nor any of its research analysts, nor any member of the ARM Group, gives any representation or warranty, express or implied, or undertaking of any kind or assumes responsibility or liability of any kind with respect to the accuracy or completeness of the information set out in this report or any third party's use (or the results of such use) of such information. This report is provided solely for informational purposes and is not to be construed as providing advice, recommendations, or endorsements of any kind whatsoever. The investments and strategies discussed here may not be suitable for all investors; counsel of investment advisor should be obtained with regard to such investments and or strategies. This research report is not a replacement for advice from an accountant, lawyer, personal finance advisor or other category of investment advisor. The investments discussed in this report may oscillate in price or value. Opinions and information provided are made as of the date of the report issue and are subject to change without notice. This research report is not intended as an offer or solicitation for the purchase or sale of any financial instrument. Reference herein to any specific security or financial instrument does not necessarily constitute or imply its endorsement or recommendation by ARMS, its directors, officers, employees or designated agents. Members of ARM may act as broker, advisor or lender, or make a market in any investments or issuers referenced in this report. Further information on any of the securities discussed herein may be obtained upon request to ARMS. By accepting this document, you agree to be bound by the foregoing limitations.